Holen Sie sich die Stockscreener-App
17.03
0.99%
-0.12
Schlusskurs vom Vortag:
$17.15
Offen:
$17.25
24-Stunden-Volumen:
991.20K
Relative Volume:
0.31
Marktkapitalisierung:
$2.42B
Einnahmen:
$62.38M
Nettoeinkommen (Verlust:
$-101.59M
KGV:
-19.70
EPS:
-0.8644
Netto-Cashflow:
$-139.93M
1W Leistung:
+0.17%
1M Leistung:
+31.62%
6M Leistung:
+160.02%
1J Leistung:
+812.88%
1-Tages-Spanne:
$16.77
$17.40
1-Wochen-Bereich:
$16.11
$17.40
52-Wochen-Spanne:
$1.03
$17.63
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
17.00 | 2.45B | 62.38M | -101.59M | -139.93M | -0.8644 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.22 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.32 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Mizuho Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) - Bitget
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Adam Crystal Sells 20,251 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data - Investing.com India
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration? - Yahoo Finance
Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data By Investing.com - Investing.com Australia
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple - Yahoo Finance
Tango Therapeutics (TNGX) Soars 52% on Buy Reco - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP) - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Blue Owl Capital Holdings LP Sells 695,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cooper Co (COO) and CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Tango Therapeutics (TNGX) Q4 Revenue Collapse To US$0 Reinforces Bearish Volatility Narrative - simplywall.st
New hire gets options on 367,500 Tango Therapeutics shares - Stock Titan
Tango Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Wedbush Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Tango Therapeutics Stock Surges 36% on Strong Q4 Results, Pipeline Momentum and Cash Runway Extension - International Business Times Australia
Tango Therapeutics (NASDAQ:TNGX) Given New $20.00 Price Target at Guggenheim - MarketBeat
Tango Therapeutics (TNGX) Q4 Loss Narrows to $0.29/Share vs $0.33 Estimate; Shares Surge 23% - AlphaStreet
Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to $27.00 at HC Wainwright - MarketBeat
4 Analysts Have This To Say About Tango Therapeutics - Benzinga
Rafferty Asset Management LLC Purchases New Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics (TNGX) hits all-time high as analyst turns bullish - MSN
Stocks to Watch Right Now: EcoPetrol, Credo, Sable Offshore, and More - Insider Monkey
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish - Insider Monkey
Jefferies raises Tango Therapeutics stock price target on RAS deal By Investing.com - Investing.com UK
Jefferies raises Tango Therapeutics stock price target on RAS deal - Investing.com Nigeria
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango Therapeutics stock hits 52-week high at $13.66 By Investing.com - Investing.com Australia
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Tango Therapeutics stock hits 52-week high at $13.66 - Investing.com Nigeria
Tango Therapeutics Shares Rise After Q4 Loss Narrows - marketscreener.com
Stifel reiterates Tango Therapeutics stock Buy rating at $15 By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Stifel reiterates Tango Therapeutics stock Buy rating at $15 - Investing.com
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Tango Therapeutics Hits Day High with Strong 7.39% Intraday Surge - Markets Mojo
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):